Francesco Passamonti

List of Publications by Year
in descending order

306	28,255	8755	5829
papers	citations	75 h-index	161 g-index

315	315	315	12433
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders. New England Journal of Medicine, 2005, 352, 1779-1790.	27.0	3,240
2	New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 2009, 113, 2895-2901.	1.4	1,110
3	DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 2011, 29, 392-397.	1.6	854
4	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	1.4	814
5	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115, 1703-1708.	1.4	805
6	Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. Journal of Clinical Oncology, 2005, 23, 7594-7603.	1.6	804
7	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	1.6	724
8	Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine, 2015, 372, 426-435.	27.0	720
9	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 2013, 27, 1874-1881.	7.2	540
10	CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia, 2014, 28, 1472-1477.	7.2	465
11	Development and validation of an International Prognostic Score of thrombosis in World Health Organizationâ€“essential thrombocythemia (IPSET-thrombosis). Blood, 2012, 120, 5128-5133.	1.4	461
12	Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia, 2008, 22, 437-438.	7.2	443
13	Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. Journal of Clinical Oncology, 2011, 29, 3179-3184.	1.6	441
14	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
15	Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medicine, 2004, 117, 755-761.	1.5	415
16	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia, 2018, 32, 1057-1069.	7.2	415
17	Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood, 2013, 122, 4047-4053.	1.4	383
18	Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood, 2011, 117, 5857-5859.	1.4	376

#	Article	IF	Citations
19	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	1.6	373
20	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis. JAMA Oncology, 2015, 1, 643.	7.1	362
21	Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs. Journal of Clinical Oncology, 2012, 30, 4098-4103.	1.6	344
22	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, 2010, 24, 1574-1579.	7.2	321
23	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood, 2013, 122, 1395-1398.	1.4	286
24	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	1.4	280
25	Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 2008, 111, 1686-1689.	1.4	264
26	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematology,the, 2017, 4, e317-e324.	4.6	243
27	Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia, 2015, 29, 2126-2133.	7.2	242
28	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	7.2	242
29	Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica, 2008, 93, 1645-1651.	3.5	241
30	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 2006, 107, 3676-3682.	1.4	236
31	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	1.4	229
32	Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. Journal of Clinical Oncology, 2009, 27, 754-762.	1.6	225
33	A prognostic model to predict survival in 867 World Health Organizationâ€“defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 2012, 120, 1197-1201.	1.4	222
34	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood, 2013, 121, 4778-4781.	1.4	219
35	Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis. Journal of Clinical Oncology, 2009, 27, 4563-4569.	1.6	213
36	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematology,the, 2018, 5, e73-e81.	4.6	211

#	Article	IF	Citations
37	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 2012, 120, 1202-1209.	1.4	205
38	Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncology, The, 2017, 18, 88-99.	10.7	205
39	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, 2011, 117, 2813-2816.	1.4	190
40	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
41	Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. American Journal of Hematology, 2014, 89, E121-4.	4.1	176
42	Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia, 2008, 22, 905-914.	7.2	175
43	Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 2005, 106, 3374-3376.	1.4	166
44	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	4.1	165
45	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood, 2010, 116, 2857-2858.	1.4	153
46	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	1.4	153
47	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood, 2015, 125, 3347-3350.	1.4	152
48	Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood, 2007, 110, 485-489.	1.4	148
49	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	2.5	144
50	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 2016, 101, 821-829.	3.5	140
51	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	1.4	137
52	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood, 2009, 114, 3538-3545.	1.4	135
53	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia, 2010, 24, 1290-1298.	7.2	135
54	Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation. Journal of Clinical Oncology, 2007, 25, 5630-5635.	1.6	130

#	Article	IF	Citations
55	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1223-1233.	1.6	127
56	Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer, 2004, 100, 107-115.	4.1	121
57	JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia, 2011, 25, 218-225.	7.2	117
58	In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood, 2014, 124, 3021-3023.	1.4	112
59	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. Annals of Oncology, 2007, 18, 346-350.	1.2	111
60	A dynamic prognostic model to predict survival in postâ€“polycythemia vera myelofibrosis. Blood, 2008, 111, 3383-3387.	1.4	108
61	Improving Survival Trends in Primary Myelofibrosis: An International Study. Journal of Clinical Oncology, 2012, 30, 2981-2987.	1.6	105
62	Hydroxyureaâ€related toxicity in 3,411 patients with Ph'â€negative MPN. American Journal of Hematology, 2012, 87, 552-554.	4.1	105
63	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia, 2018, 32, 1200-1210.	7.2	101
64	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the <scp>JAKARTA2</scp> study using stringent criteria for ruxolitinib failure. American Journal of Hematology, 2020, 95, 594-603.	4.1	96
65	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 2014, 123, 1833-1835.	1.4	95
66	Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematology,the, 2020, 7, e226-e237.	4.6	93
67	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. Haematologica, 2010, 95, 1792-1796.	3.5	91
68	Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood, 2012, 119, 2239-2241.	1.4	90
69	Platelet size distinguishes between inherited macrothrombocytopenias and immune thrombocytopenia. Journal of Thrombosis and Haemostasis, 2009, 7, 2131-2136.	3.8	86
70	What are RBC-transfusion-dependence and -independence?. Leukemia Research, 2011, 35, 8-11.	0.8	84
71	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood, 2013, 121, 4388-4395.	1.4	83
72	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer, 2006, 107, 2206-2211.	4.1	82

#	Article	IF	Citations
73	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
74	Leukemic transformation of polycythemia vera. Cancer, 2005, 104, 1032-1036.	4.1	79
75	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123, 3803-3810.	1.4	79
76	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood, 2014, 124, 2611-2612.	1.4	79
77	Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica, 2009, 94, 7-10.	3.5	78
78	Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal of Haematology, 2007, 136, 301-304.	2.5	76
79	Healthâ€related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. British Journal of Haematology, 2013, 162, 229-239.	2.5	75
80	Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up. Clinical Cancer Research, 2006, 12, 6487-6493.	7.0	74
81	How I treat polycythemia vera. Blood, 2012, 120, 275-284.	1.4	74
82	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	1.4	70
83	Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood, 2012, 120, 569-571.	1.4	69
84	The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, doubleâ€blind, doubleâ€dummy, symptom study (RELIEF). British Journal of Haematology, 2017, 176, 76-85.	2.5	69
85	The â€˜GGCCâ€™ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia, 2009, 23, 1924-1926.	7.2	68
86	Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica, 2003, 88, 13-8.	3.5	68
87	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica, 2011, 96, 367-374.	3.5	67
88	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nature Communications, 2018, 9, 2192.	12.8	66
89	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica, 2011, 96, 454-458.	3.5	65
90	Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica, 2011, 96, 607-611.	3.5	64

#	Article	IF	Citations
91	Nongastric Marginalâ€Zone Bâ€Cell MALT Lymphoma: Prognostic Value of Disease Dissemination. Oncologist, 2006, 11, 285-291.	3.7	63
92	Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. British Journal of Haematology, 2008, 140, 162-168.	2.5	60
93	Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Annals of Oncology, 2009, 20, 129-136.	1.2	60
94	Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica, 2011, 96, 167-170.	3.5	60
95	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Journal of Clinical Oncology, 2016, 34, 151-159.	1.6	56
96	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
97	A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence. Leukemia, 2017, 31, 896-902.	7.2	54
98	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. Blood, 2019, 134, 557-557.	1.4	54
99	Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Annals of Hematology, 2018, 97, 1591-1600.	1.8	53
100	Impact of treatmentâ€related liver toxicity on the outcome of HCVâ€positive nonâ€Hodgkin's lymphomas. American Journal of Hematology, 2010, 85, 46-50.	4.1	52
101	JAK Inhibitor in CALR-Mutant Myelofibrosis. New England Journal of Medicine, 2014, 370, 1168-1169.	27.0	52
102	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	1.4	52
103	Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. Oncologist, 2019, 24, e720-e729.	3.7	52
104	Pityriasis roseaâ€“like eruption during treatment with imatinib mesylate: Description of 3 cases. Journal of the American Academy of Dermatology, 2005, 53, S240-S243.	1.2	50
105	Leukocytosis as an important risk factor for arterial thrombosis in WHOâ€defined early/prefibrotic myelofibrosis: An international study of 264 patients. American Journal of Hematology, 2012, 87, 669-672.	4.1	49
106	Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood, 2016, 127, 362-365.	1.4	49
107	Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747.	1.4	49
108	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a PCM1-JAK2 Fusion Gene. Journal of Clinical Oncology, 2013, 31, e269-e271.	1.6	47

#	Article	IF	Citations
109	Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases. Thrombosis Research, 2014, 134, 41-43.	1.7	47
110	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	4.1	47
111	A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis. Blood Advances, 2022, 6, 1855-1864.	5.2	47
112	Transfusionâ€dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosisâ€"prognostic relevance is independent of IPSS or karyotype. American Journal of Hematology, 2010, 85, 14-17.	4.1	46
113	Subcutaneous â€˜lipoma-likeâ€™ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT. Annals of Oncology, 2010, 21, 1189-1195.	1.2	46
114	Changes in quality of life and diseaseâ€related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. European Journal of Haematology, 2016, 97, 192-200.	2.2	46
115	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	3.5	46
116	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Advances, 2022, 6, 2427-2433.	5.2	46
117	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematology,the, 2022, 9, e301-e311.	4.6	46
118	Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia, 2012, 26, 1439-1441.	7.2	45
119	Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget, 2011, 2, 485-490.	1.8	44
120	Update from the latest WHO classification of MPNs: a userâ€™s manual. Hematology American Society of Hematology Education Program, 2016, 2016, 534-542.	2.5	42
121	Driver mutationsâ€™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia, 2017, 31, 970-973.	7.2	41
122	JAK2 (V617F) mutation in healthy individuals. British Journal of Haematology, 2007, 136, 678-679.	2.5	40
123	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals of Oncology, 2008, 19, 1331-1335.	1.2	40
124	Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia, 2015, 29, 20-26.	7.2	40
125	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. Leukemia, 2017, 31, 882-888.	7.2	40
126	The role of JAK2 inhibitors in MPNs 7 years after approval. Blood, 2018, 131, 2426-2435.	1.4	40

#	Article	IF	Citations
127	Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. European Journal of Haematology, 2015, 94, 31-36.	2.2	39
128	Identification of genomic aberrations associated with disease transformation by means of highâ€resolution SNP array analysis in patients with myeloproliferative neoplasm. American Journal of Hematology, 2011, 86, 974-979.	4.1	37
129	Clinical relevance of clonal hematopoiesis in persons aged â‰¥80 years. Blood, 2021, 138, 2093-2105.	1.4	37
130	Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. British Journal of Haematology, 2002, 116, 855-861.	2.5	36
131	Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology, 2004, 126, 650-656.	2.5	36
132	Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. Journal of Thrombosis and Haemostasis, 2010, 8, 411-413.	3.8	36
133	Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. British Journal of Haematology, 2010, 149, 455-457.	2.5	36
134	Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia, 2002, 16, 2078-2083.	7.2	35
135	Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia. American Journal of Hematology, 2006, 81, 124-127.	4.1	35
136	Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study. Blood Advances, 2022, 6, 373-375.	5.2	34
137	Survival in young patients with intermediateâ€/highâ€risk myelofibrosis: Estimates derived from databases for non transplant patients. American Journal of Hematology, 2009, 84, 140-143.	4.1	33
138	Long-Term Safety, Efficacy, and Survival Findings From Comfort-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy (BAT) for the Treatment of Myelofibrosis (MF). Blood, 2012, 120, 801-801.	1.4	33
139	Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica, 2003, 88, 1123-9.	3.5	33
140	Combination of Rituximab, Cyclophosphamide, and Vincristine Induces Complete Hematologic Remission of Splenic Marginal Zone Lymphoma. Clinical Lymphoma and Myeloma, 2004, 4, 250-252.	2.1	32
141	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	4.5	32
142	correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBCâ€“transfusionâ€dependence. British Journal of Haematology, 2010, 150, 719-721.	2.5	31
143	A novel germline JAK2 mutation in familial myeloproliferative neoplasms. American Journal of Hematology, 2014, 89, 117-118.	4.1	31
144	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	3.5	31

#	Article	IF	Citations
145	Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances, 2020, 4, 3708-3715.	5.2	31
146	Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations. American Journal of Hematology, 2009, 84, 629-630.	4.1	30
147	Increase in leukocyte count over time predicts thrombosis in patients with lowâ€risk essential thrombocythemia. Journal of Thrombosis and Haemostasis, 2009, 7, 1587-1589.	3.8	30
148	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. Blood Cells, Molecules, and Diseases, 2009, 42, 286-291.	1.4	30
149	Assessment of bone marrow involvement in nonâ€Hodgkinâ€™s lymphomas: comparison between histology and flow cytometry. European Journal of Haematology, 2010, 85, 405-415.	2.2	30
150	Evidence- and consensus-based recommendations for phlebotomy in polycythemia vera. Leukemia, 2018, 32, 2077-2081.	7.2	30
151	Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. American Journal of Hematology, 2012, 87, 203-204.	4.1	29
152	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. HemaSphere, 2021, 5, e612.	2.7	29
153	A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.. Blood, 2009, 114, 311-311.	1.4	29
154	Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. The Cochrane Library, 2013, , CD006503.	2.8	28
155	Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. Leukemia Research, 2014, 38, 155-160.	0.8	28
156	A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. Journal of Hematology and Oncology, 2018, 11, 122.	17.0	28
157	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	5.2	28
158	A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 384-387.	2.4	27
159	Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. Journal of Internal Medicine, 2009, 265, 266-274.	6.0	26
160	New generation small-molecule inhibitors in myeloproliferative neoplasms. Current Opinion in Hematology, 2012, 19, 117-123.	2.5	25
161	Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia, 2021, 35, 3455-3465.	7.2	25
162	Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Annals of Hematology, 2004, 83, 495-7.	1.8	24

#	Article	IF	Citations
163	Use of the Functional Assessment of Cancer Therapyâ”Anemia in Persons with Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia. Clinical Therapeutics, 2014, 36, 560-566.	2.5	24
164	Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study. Blood, 2020, 136, 47-48.	1.4	24
165	Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer, 2022, 128, 2420-2432.	4.1	24
166	New molecular genetics in the diagnosis and treatment of myeloproliferative neoplasms. Current Opinion in Hematology, 2016, 23, 137-143.	2.5	23
167	Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Annals of Hematology, 2018, 97, 617-627.	1.8	23
168	Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia, 2014, 28, 1357-1360.	7.2	22
169	Results Of a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). Blood, 2013, 122, 393-393.	1.4	22
170	High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. Human Pathology, 2009, 40, 1628-1637.	2.0	21
171	Everolimus in diffuse large B-cell lymphomas. Future Oncology, 2015, 11, 373-383.	2.4	20
172	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. HemaSphere, 2021, 5, e562.	2.7	20
173	Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment. Leukemia Research, 2006, 30, 277-282.	0.8	19
174	Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHOâ€criteria and stratified by calendar period of diagnosis. American Journal of Hematology, 2015, 90, 434-437.	4.1	19
175	Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis. Current Hematologic Malignancy Reports, 2018, 13, 173-182.	2.3	19
176	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.8	18
177	Stem cell transplant in MF: itâ€™s time to personalize. Blood, 2019, 133, 2118-2120.	1.4	18
178	Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Advances, 2019, 3, 3196-3200.	5.2	18
179	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinaseâ€2 (<scp>JAK2</scp>), in patients with myelofibrosis and low pretreatment platelet counts. British Journal of Haematology, 2022, 198, 317-327.	2.5	18
180	Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematology,the, 2022, 9, e480-e492.	4.6	18

#	Article	IF	Citations
181	Exaggerated Insect Bite-like Reaction in Patients Affected by Oncohaematological Diseases. Acta Dermato-Venereologica, 2005, 85, 76-77.	1.3	17
182	It is time to change thrombosis risk assessment for PV and ET?. Best Practice and Research in Clinical Haematology, 2014, 27, 121-127.	1.7	16
183	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer, 2016, 122, 1888-1896.	4.1	16
184	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	2.8	16
185	Eltrombopag for immune thrombocytopenia secondary to chronic lymphoproliferative disorders: a phase 2 multicenter study. Blood, 2019, 134, 1708-1711.	1.4	16
186	How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italyâ€”a GIMEMA MPN WP survey. Leukemia, 2020, 34, 2805-2808.	7.2	16
187	COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. Leukemia, 2020, 34, 2813-2814.	7.2	16
188	Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-NaÃ¯ve or were Previously Treated with Ruxolitinib. Blood, 2019, 134, 668-668.	1.4	16
189	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012;97(3):360-5 - Comment. Haematologica, 2012, 97, e5-e6.	3.5	15
190	Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 2122-2128.	1.3	15
191	The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). Blood, 2013, 122, 4070-4070.	1.4	15
192	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). Haematologica, 2023, 108, 22-33.	3.5	15
193	Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).. Journal of Clinical Oncology, 2017, 35, 7001-7001.	1.6	14
194	Disease anticipation in familial myeloproliferative neoplasms. Blood, 2008, 112, 2587-2588.	1.4	13
195	Mutational Status of Myeloproliferative Neoplasms. Critical Reviews in Eukaryotic Gene Expression, 2010, 20, 61-76.	0.9	13
196	Novel agents in indolent lymphomas. Therapeutic Advances in Hematology, 2013, 4, 133-148.	2.5	13
197	Ruxolitinib and survival improvement in patients with myelofibrosis. Leukemia, 2015, 29, 739-740.	7.2	13
198	Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2016, 46, 18-25.	0.8	13

#	Article	IF	Citations
199	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia Research, 2018, 69, 100-102.	0.8	13
200	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	6.2	13
201	Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma. Oncology, 2005, 68, 146-153.	1.9	12
202	Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkinâ€™s lymphoma. Expert Opinion on Investigational Drugs, 2015, 24, 897-912.	4.1	12
203	Validation of the â€œfitness criteriaâ€• for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL). Journal of Geriatric Oncology, 2021, 12, 550-556.	1.0	12
204	Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman. Leukemia and Lymphoma, 2003, 44, 1483-1488.	1.3	12
205	Pomalidomide Therapy in Myelofibrosis: 2-Year Follow-up of a Randomized Phase 2 Study.. Blood, 2009, 114, 1904-1904.	1.4	12
206	New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. Expert Review of Hematology, 2016, 9, 767-780.	2.2	11
207	Directâ€acting antivirals during or after immunochemotherapy in hepatitis C virusâ€“positive diffuse large Bâ€cell lymphomas. Hepatology, 2017, 66, 1341-1343.	7.3	11
208	Developments in diagnosis and treatment of essential thrombocythemia. Expert Review of Hematology, 2019, 12, 159-171.	2.2	11
209	Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System lowâ€, intermediateâ€1â€, intermediateâ€2â€, and highâ€risk myelofibrosis in JUMP, a Phase 3b, expandedâ€access study. Hematological Oncology, 2021, 39, 558-566.	1.7	11
210	Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation. Bone Marrow Transplantation, 2021, , .	2.4	11
211	Deferasirox in the management of ironâ€overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (<scp>IRON</scp>â€M study). British Journal of Haematology, 2019, 186, e123-e126.	2.5	10
212	The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances, 2022, 6, 1162-1174.	5.2	10
213	Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplantation, 2010, 45, 798-800.	2.4	9
214	Prognostic Factors and Models in Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S25-S27.	0.4	9
215	How to manage polycythemia vera. Leukemia, 2012, 26, 870-874.	7.2	9
216	Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis. Cancers, 2021, 13, 4744.	3.7	9

#	Article	IF	Citations
217	Treatment of Polycythemia Vera and Essential Thrombocythemia: The Role of Pipobroman. Leukemia and Lymphoma, 2003, 44, 1483-1488.	1.3	8
218	PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. Leukemia, 2005, 19, 888-889.	7.2	8
219	Risk of Second Cancer in Nongastric Marginal Zone B-Cell Lymphomas of Mucosa-Associated Lymphoid Tissue: A Population-Based Study from Northern Italy. Clinical Cancer Research, 2007, 13, 182-186.	7.0	8
220	Blast phase of essential thrombocythemia: A single center study. American Journal of Hematology, 2009, 84, 641-644.	4.1	8
221	Bayesian models identify specific lymphoproliferative disorders associated with hepatitis C virus infection. International Journal of Cancer, 2009, 124, 2246-2249.	5.1	8
222	Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e324-e335.	3.8	8
223	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	4.1	8
224	Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders. Clinical Hematology International, 2021, 3, 77.	1.7	8
225	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	5.2	8
226	Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios. Cancers, 2021, 13, 4750.	3.7	8
227	Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy. Blood, 2011, 118, 793-793.	1.4	8
228	High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.. Blood, 2007, 110, 2620-2620.	1.4	8
229	The future of research in hematology: Integration of conventional studies with real-world data and artificial intelligence. Blood Reviews, 2022, 54, 100914.	5.7	8
230	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Advances, 2022, 6, 3870-3874.	5.2	8
231	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virusâ€“Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2022, 40, 4060-4070.	1.6	8
232	Immunogenicity and clinical efficacy of antiâ€SARSâ€CoVâ€2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients. American Journal of Hematology, 2022, 97, .	4.1	8
233	Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. Haematologica, 2011, 96, 1236-1238.	3.5	7
234	A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion. Leukemia and Lymphoma, 2017, 58, 1977-1980.	1.3	7

#	Article	IF	Citations
235	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. HemaSphere, 2021, 5, e553.	2.7	7
236	Mechanisms of Adaptation to Ibrutinib in High Risk Chronic Lymphocytic Leukemia. Blood, 2018, 132, 585-585.	1.4	7
237	Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia.. Blood, 2009, 114, 435-435.	1.4	7
238	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. Blood, 2011, 118, 277-277.	1.4	7
239	Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients. Blood, 2010, 116, 5060-5060.	1.4	7
240	Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica, 2006, 91, 159.	3.5	7
241	Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. Clinical Advances in Hematology and Oncology, 2017, 15, 700-707.	0.3	7
242	Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review. Future Oncology, 2022, 18, 2217-2231.	2.4	7
243	Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia and Lymphoma, 2006, 47, 1018-1022.	1.3	6
244	Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood, 2010, 115, 2719-2720.	1.4	6
245	RBC-transfusion guidelines update. Leukemia Research, 2012, 36, 659-660.	0.8	6
246	Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma. Expert Opinion on Investigational Drugs, 2017, 26, 367-373.	4.1	6
247	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. Leukemia, 2020, 34, 929-931.	7.2	6
248	Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. Blood, 2012, 120, 804-804.	1.4	6
249	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	1.4	6
250	The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis. Antioxidants, 2022, 11, 113.	5.1	6
251	HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. Leukemia and Lymphoma, 2007, 48, 805-807.	1.3	5
252	Clinical Predictors of Outcome in MPN. Hematology/Oncology Clinics of North America, 2012, 26, 1101-1116.	2.2	5

#	Article	IF	Citations
253	Platelet count predicts driver mutationsâ€™ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis. Leukemia, 2021, 35, 1490-1493.	7.2	5
254	Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) without Splenomegaly: 5-Year Results from the Phase 3 Response-2 Study. Blood, 2020, 136, 40-41.	1.4	5
255	Looking for familial nodular lymphocyteâ€predominant Hodgkin lymphoma. American Journal of Hematology, 2013, 88, 719-720.	4.1	4
256	Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e324-e335.	3.8	4
257	Standard care and investigational drugs in the treatment of myelofibrosis. Drugs in Context, 2019, 8, 1-16.	2.2	4
258	New and old prognostic factors in polycythemia vera. Current Hematologic Malignancy Reports, 2009, 4, 19-24.	2.3	3
259	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. British Journal of Haematology, 2018, 182, 279-284.	2.5	3
260	Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative. American Journal of Hematology, 2019, 94, E239-E242.	4.1	3
261	Directâ€acting antivirals in hepatitis C virusâ€positive mantle cell lymphomas. Hematological Oncology, 2021, 39, 263-266.	1.7	3
262	Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leukemia and Lymphoma, 2022, 63, 189-198.	1.3	3
263	Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study.. Blood, 2009, 114, 3904-3904.	1.4	3
264	Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.. Journal of Clinical Oncology, 2022, 40, 7015-7015.	1.6	3
265	Balancing efficacy and safety of JAK inhibitors in myelofibrosis. Leukemia Research, 2014, 38, 290-291.	0.8	2
266	Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy. Journal of the Neurological Sciences, 2014, 344, 234-235.	0.6	2
267	Response to â€œQuestions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisionsâ€•by Heidel et al.. Leukemia, 2018, 32, 2727-2728.	7.2	2
268	Chronic myeloproliferative neoplasms in the elderly. European Journal of Internal Medicine, 2018, 58, 33-42.	2.2	2
269	A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!. American Journal of Hematology, 2019, 94, 1303-1305.	4.1	2
270	The EHA Research Roadmap: Malignant Myeloid Diseases. HemaSphere, 2021, 5, e635.	2.7	2

#	Article	IF	Citations
271	Bendamustine in Combination with Gemcitabine and Vinorelbine (BEGEV) Is an Effective Regimen for Heavily Pretreated, Relapsed/Refractory Hodgkin Lymphoma Patients: A Multicenter, Retrospective Real-World Study. Blood, 2018, 132, 1655-1655.	1.4	2
272	Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study. Blood, 2019, 134, 704-704.	1.4	2
273	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. Blood, 2019, 134, 4165-4165.	1.4	2
274	The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome.. Blood, 2005, 106, 791-791.	1.4	2
275	Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra-Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). Blood, 2010, 116, 1973-1973.	1.4	2
276	Classification of Myeloproliferative Neoplasms and Prognostic Factors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 419-424.	3.8	2
277	Therapy of polycythemia vera: is it time to change?. Oncotarget, 2017, 8, 102759-102760.	1.8	2
278	Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. American Journal of Hematology, 2012, 87, 129-130.	4.1	1
279	PDGFRB disease: right diagnosis to prolong survival. Blood, 2014, 123, 3526-3528.	1.4	1
280	Analysis of three screening methods for the detection of calreticulin gene mutations. International Journal of Laboratory Hematology, 2020, 42, e76-e79.	1.3	1
281	Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 987-989.	1.3	1
282	Bortezomib-based therapy in non-transplant multiple myeloma patients: a retrospective cohort study from the FABIO project. Therapeutic Advances in Hematology, 2021, 12, 204062072199648.	2.5	1
283	The double significance of idelalisib immune-related toxicity. Leukemia and Lymphoma, 2021, 62, 1-3.	1.3	1
284	Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review. Blood, 2020, 136, 23-23.	1.4	1
285	Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.. Blood, 2007, 110, 263-263.	1.4	1
286	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires.. Blood, 2008, 112, 1775-1775.	1.4	1
287	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. Blood, 2019, 134, 2207-2207.	1.4	1
288	Adherence to Treatment in Myelofibrosis Patients: Preliminary Results from Italian Romei Observational Study. Blood, 2019, 134, 4179-4179.	1.4	1

#	Article	IF	Citations
289	COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A) Tj ETQq1 1 0.784314 rgBT /Over		
290	Ibrutinib dose intensity in highâ€risk chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 1100-1104.	1.7	1
291	Management of Post ET/PV MF: Different from Primary MF. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S24-S26.	0.4	0
292	Understanding New WHO Classification of MPNs. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S91-S92.	0.4	0
293	Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi. Bone Marrow Transplantation, 2020, 55, 2350-2353.	2.4	0
294	Polycythemia Vera: Is It Time to Rethink Treatment?. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S121-S124.	0.4	0
295	Transfusion Need at Diagnosis or Its Development During the First Year of Diagnosis in Primary Myelofibrosis: Effect On Survival and Correlation with JAK2 and TET2 Mutational Status.. Blood, 2009, 114, 1909-1909.	1.4	0
296	INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia.. Blood, 2009, 114, 2905-2905.	1.4	0
297	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. Blood, 2009, 114, 760-760.	1.4	0
298	Interim 18f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis. Blood, 2011, 118, 5183-5183.	1.4	0
299	Risk Stratification in PMF. , 2012, , 163-175.		0
300	Spliceosome Mutations Are Common in MPN-Associated Myelofibrosis with RBC-Transfusion-Dependence and Correlate with Response to Pomalidomide. Blood, 2018, 132, 3037-3037.	1.4	0
301	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. Blood, 2019, 134, 4188-4188.	1.4	0
302	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	1.4	0
303	Impact of Direct-Acting Antivirals on the Outcome of HIV/HCV Coinfected Patients with Non-Hodgkin Lymphomas in the Modern Anti-Retroviral Therapy Era: A Retrospective Multicenter Study of 74 Cases. Blood, 2021, 138, 1434-1434.	1.4	0
304	Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group. Blood, 2020, 136, 30-31.	1.4	0
305	A Sex-Informed Approach to Improve Prognostication and Personalized Decision-Making Process in Myelodysplastic Syndromes. a European Study of 11.878 Patients. Blood, 2020, 136, 23-24.	1.4	0
306	Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib. Hematological Oncology, 2022, 40, 1105-1108.	1.7	0